-+ 0.00%
-+ 0.00%
-+ 0.00%

UPSTREAM BIO PRESENTS NEW RESPONDER ANALYSES DEMONSTRATING CLINICALLY MEANINGFUL IMPROVEMENTS IN CRSWNP IN SIGNIFICANT MAJORITY OF PARTICIPANTS TREATED WITH VEREKITUG IN THE PHASE 2 VIBRANT TRIAL AT EAACI 2026

Reuters·06/14/2026 14:00:00

Please log in to view news